The opening sentence of that journal article feels off...
"Among people with prostate cancer, transgender women receiving estrogen are more likely to present with high-grade disease vs cisgender men, suggesting potential delayed diagnosis"
Given that trans women have smaller prostates (a protective factor) and lower testosterone (a protective factor) and that estrogen therapy is the leading treatment for men with prostate cancer, it feels like quite an assumption to state that lower overall presentations of high grade cancer are potentially an indication of an increased risk of high grade cancer...